The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Karpova M.I.

State educational institution of higher professional education «South Ural State Medical University», Russian Ministry of Health

Zariada A.A.

South Ural State Medical University, Russian Ministry of Health, Chelyabinsk

Dolgushina V.F.

Kafedra akusherstva i ginekologii

Korotkova D.G.

South Ural State Medical University, Russian Ministry of Health, Chelyabinsk

Ekusheva E.V.

Otdel patologii vegetativnoĭ nervnoĭ sistemy Nauchno-issledovatel'skogo tsentra Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Osipova V.V.

Research Department of Neurology, Scientific Research Center, I.M. Sechenov First Moscow State Medical University, Moscow, Russia;
Moscow Research Clinical Centre for Neuropsychiatry, Moscow Health Department, Moscow, Russia

Migraine in women: clinical and therapeutical aspects

Authors:

Karpova M.I., Zariada A.A., Dolgushina V.F., Korotkova D.G., Ekusheva E.V., Osipova V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3): 98‑107

DOI: 10.17116/jnevro201911903198

Read: 12138 times

Download PDF (RU)
Contact the author
Table of contents

MIGRAINE IN WOMEN: CLINICAL AND THERAPEUTICAL ASPECTS
MIGRAINE IN WOMEN: CLINICAL AND THERAPEUTICAL ASPECTS

To cite this article:

Karpova MI, Zariada AA, Dolgushina VF, Korotkova DG, Ekusheva EV, Osipova VV. Migraine in women: clinical and therapeutical aspects. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3):98‑107. (In Russ.)
https://doi.org/10.17116/jnevro201911903198

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Oxidative stress in the pathogenesis of chro­nic headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):35-40
Psoriasis in pregnant women. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):517-524
Local cyto­kine profile of the endo­metrium in patients with repeated implantation failures and its pharmacological correction by the secretome of peri­pheral blood mono­nuclear cells. Russian Journal of Human Reproduction. 2024;(5):46-54
Immu­nological aspe­cts of reccurent pregnancy loss. Russian Journal of Human Reproduction. 2024;(5):64-71
Pecu­liarities of placental microRNA expression in patients with preeclampsia and fetal growth restriction. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):14-25
Changes in the type of psychological component of the gestational domi­nant in pregnant women in the third trimester after completing the peri­natal preparation program. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):66-71
Expe­rience of using a drug containing poly­peptides of the bladder of cattle in the treatment of patients with overactive bladder in peri­menopause. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):91-99
Sexual function of women during pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):112-117
Dyna­mics of Substance P and Fila­ggrin Levels on Combined Treatment of Atopic Dermatitis with Emollient and Topi­cal Anti­pruritic Drug in Pregnant Women. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):662-666
Functional cyto­kine redu­ndancy in pregnancy. Russian Journal of Human Reproduction. 2024;(6):73-80
Abstract:

Migraine is one of the most common neurological disorders, affecting women. Physiological changes in the hormonal status can modulate the functional status of pain and analgesic systems of the brain and, by involving different pathophysiological mechanisms, change the course of migraine. In addition to an analysis of epidemiological data, the review provides current views on the clinical features of the disease in women population at different periods of life, particular attention was focused on menstrual migraine. It has certain features, such as acute and long attacks and treatment difficulties. One of main issues is the use of oral contraceptives in women with migraine according to the ratio of potential benefit to cardiovascular risk. The problems of treatment headaches in pregnant and breastfeeding women are also considered. An influence of migraine on the course and outcome of pregnancy was shown. The authors analysed the results of the studies on the course of migraine during perimenopause and postmenopause and recommendations for women with migraine attacks and climacteric syndrome. The data presented in the review are useful for clinicians, because this information represents new views on pathogenetic mechanisms, clinical features and treatment of migraine in women.

Keywords:

migraine
menstrual migraine
estrogens
menstruation
pregnancy
lactation
perimenopause
postmenopause

Authors:

Karpova M.I.

State educational institution of higher professional education «South Ural State Medical University», Russian Ministry of Health

Zariada A.A.

South Ural State Medical University, Russian Ministry of Health, Chelyabinsk

Dolgushina V.F.

Kafedra akusherstva i ginekologii

Korotkova D.G.

South Ural State Medical University, Russian Ministry of Health, Chelyabinsk

Ekusheva E.V.

Otdel patologii vegetativnoĭ nervnoĭ sistemy Nauchno-issledovatel'skogo tsentra Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Osipova V.V.

Research Department of Neurology, Scientific Research Center, I.M. Sechenov First Moscow State Medical University, Moscow, Russia;
Moscow Research Clinical Centre for Neuropsychiatry, Moscow Health Department, Moscow, Russia

Close metadata

References:

  1. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008;28:1170-1178. https://doi.org/10.1111/j.1468-2982.2008.01666.x
  2. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology. 1999;53(3):537-542. https://doi.org/10.1212/wnl.53.3.537
  3. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349. https://doi.org/10.1212/01.wnl.0000252808.97649.21
  4. Vetvik KG, Benth JS, MacGregor EA, Lundqvist C, Russell MB. Menstrual versus non-menstrual attacks of migraine without aura in women with and without menstrual migraine. Cephalalgia. 2015;35(14):1261-1268. https://doi.org/10.1177/0333102415575723
  5. Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol. 2015;14(1):65-80. https://doi.org/10.1016/s1474-4422(14)70220-0
  6. Boardman HF, Thomas E, Croft PR, Millson DS. Epidemiology of headache in an English district. Cephalalgia. 2003;23(2):129-137. https://doi.org/10.1046/j.1468-2982.2003.00468.x
  7. Serousova OV, Karpova MI, Dolgushina AI, Vasilenko AF, Markova VV, Altman DSh. Klinicheskoye znacheniye toshnoty pri migreni. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(1(2)):43-47. (In Russ.)
  8. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study. Headache. 2007;47:355-363. https://doi.org/10.1111/j.1526-4610.2006.00631.x
  9. Le H, Tfelt-Hansen P, Russell MB, Skytthe A, Kyvik KO, Olesen J. Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia. 2011;31:43-64. https://doi.org/10.1177/0333102410373159
  10. Dowson AJ, Kilminster SG, Salt R, Clark M, Bundy MJ. Disability associated with headaches occurring inside and outside the menstrual period in those with migraine: A general practice study. Headache. 2005;45:274-282. https://doi.org/10.1111/j.1526-4610.2005.05064.x
  11. Radtke A, Neuhauser H. Prevalence and burden ofheadache and migraine in Germany. Headache. 2009;49:79-89. https://doi.org/10.1111/j.1526-4610.2008.01263.x
  12. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2018;38:1-211. https://doi.org/10.1177/0333102417738202
  13. Gromova SA, Tabeeva GR. Catamenial migraine: epidemiology, pathogenesis, diagnosis, clinical features. Nevrologiya, Neyropsikhiatriya, Psikhosomatika. 2010;2:11-18. (In Russ.)
  14. Couturier EG, Bomhof MA, Neven AK, Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23:302-308. https://doi.org/10.1046/j.1468-2982.2003.00516.x
  15. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63(2):351-353. https://doi.org/10.1212/01.wnl.0000133134.68143.2e
  16. Pavlovic JM, Allshouse AA, Santoro NF, Crawford SL, Thurston RC, Neal-Perry GS, Lipton RB, Derby CA. Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. Neurology. 2016;87:49-56. https://doi.org/10.1212/wnl.0000000000002798
  17. Herzog AG. Neuroactive properties of reproductive steroids. Headache. 2007;47(2):68-78. https://doi.org/10.1111/j.1526-4610.2007.00817.x
  18. Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis. Part I. Headache. 2006;46:3-23. https://doi.org/10.1111/j.1526-4610.2006.00309.x
  19. Nattero G, Allais G, De Lorenzo C, Benedetto C, Zonca M, Melzi E, Massobrio M. Relevance of prostaglandins in true menstrual migraine. Headache. 1989;29(04):233-238. https://doi.org/10.1111/j.1526-4610.1989.hed22904233.x
  20. Chauvel V, Multon S, Schoenen J. Estrogen-dependent effects of 5-hydroxytryptophan on cortical spreading depression in rat: Modelling the serotonin-ovarian hormone interaction in migraine aura. Cephalalgia. 2017;38(3):427-436. https://doi.org/10.1177/0333102417690891
  21. Tepper SJ. Tailoring management strategies for the patient with menstrual migraine: Focus on prevention and treatment. Headache. 2006;46(2):61-68. https://doi.org/10.1111/j.1526-4610.2006.00556.x
  22. MacGregor EA. A review of frovatriptan for the treatment of menstrual migraine. Int J Womens Health. 2014;6:523-535. https://doi.org/10.2147/ijwh.s63444
  23. Bussone G, Allais G, Castagnoli Gabellari I, Benedetto C. Almotriptan for menstrually related migraine. Expert Opin Pharmacother. 2011;12(12):1933-1943. https://doi.org/10.1517/14656566.2011.594794
  24. Allais G, Bussone G, D’Andrea G, Moschiano F, Onofrio F, Valguarnera F, Manzoni GC, Grazzi L, Allais R, Benedetto C, Acuto G. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2010;31(02):144-151. https://doi.org/10.1177/0333102410378048
  25. Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C; French Naramig Collaborative Study Group. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol. 2005;12(10):774-781. https://doi.org/10.1111/j.1468-1331.2005.01076.x
  26. Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol. 1993;82(05):769-772. https://doi.org/10.1016/0091-2182(94)90101-5
  27. Schreiber CP, Cady RK. Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg. Clin Ther. 2007;29:2511-2519. https://doi.org/10.1016/j.clinthera.2007.11.018
  28. Landy S, Savani N, Shackelford S, Loftus J, Jones M. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract. 2004;58(10):913-919. https://doi.org/10.1111/j.1368-5031.2004.00295.x
  29. Nett R, Landy S, Shackelford S, Richardson MS, Ames M, Lener M. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol. 2003;102(04):835-842. https://doi.org/10.1097/00006250-200310000-00027
  30. Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000;96(02):237-242. https://doi.org/10.1097/00006250-200008000-00016
  31. Mannix LK, Loder E, Nett R, Mueller L, Rodgers A, Hustad CM, Ramsey KE, Skobieranda F. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007;27(05):414-421. https://doi.org/10.1111/j.1468-2982.2007.01313.x
  32. Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20(12):1019-1026. https://doi.org/10.2165/00023210-200620120-00005
  33. Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, doubleblind, placebo-controlled study. Headache. 2004;44(02):120-130. https://doi.org/10.1111/j.1526-4610.2004.04027.x
  34. Allais G, Tullo V, Omboni S, Pezzola D, Zava D, Benedetto C, Bussone G. Frovatriptan vs. other triptans for the acute treatment of oral contraceptive-induced menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies. Neurol Sci. 2013;34(1):83-86. https://doi.org/10.1007/s10072-013-1393-x
  35. Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Fierro B, Brighina F. Frovatriptan versus almotriptan for acute treatment ofmenstrualmigraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain. 2012;13(05):401-406. https://doi.org/10.1007/s10194-012-0455-4
  36. Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008;22(10):877-886. https://doi.org/10.2165/00023210-200822100-00007
  37. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63(02):261-269. https://doi.org/10.1212/01.wnl.0000134620.30129.d6
  38. Newman L, Mannix LK, Landy S, Silberstein S, Lipton RB, Putnam DG, Watson C, Jobsis M, Batenhorst A, O’Quinn S. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001;41(03):248-256. https://doi.org/10.1046/j.1526-4610.2001.111006248.x
  39. Marcus DA, Bernstein CD, Sullivan EA, Rudy TE. Perimenstrual eletriptan prevents menstrual migraine: an open-label study. Headache. 2010;50(04):551-562. https://doi.org/10.1111/j.1526-4610.2010.01628.x
  40. Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998;51(01):307-309. https://doi.org/10.1212/wnl.51.1.307
  41. Allais G, Bussone G, De Lorenzo C, Gabellari I, Zonca M, Mana O, Borgogno P, Acuto G, Benedetto C. Naproxen sodium in short-term prophylaxis of pure menstrual migraine: pathophysiological and clinical considerations. Neurol Sci. 2007;28(2):225-228. https://doi.org/10.1007/s10072-007-0783-3
  42. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium. Headache. 1991;31:298-301. https://doi.org/10.1111/j.1526-4610.1991.hed3105298.x
  43. Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol. 1988;2(02):113-120. https://doi.org/10.3109/09513598809023619
  44. de Lignières B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed). 1986;293(6561):1540. https://doi.org/10.1136/bmj.293.6561.1540
  45. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: A double-blind placebo-controlled crossover study. Neurology. 2006;67:2159-2163. https://doi.org/10.1212/01.wnl.0000249114.52802.55
  46. Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007;47(01):27-37. https://doi.org/10.1111/j.1526-4610.2007.00650.x
  47. Nappi RE, Terreno E, Sances G, Martini E, Tonani S, Santamaria V, Tassorelli C, Spinillo A. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception. 2013;88(3):369-375. https://doi.org/10.1016/j.contraception.2013.02.001
  48. Osipova VV, Filatova EG, Artemenko AR, Lebedeva ER, Azimova YuE, Latysheva NV, Sergeev AV, Amelin AV, Koreshkina MI, Skorobogatyh KV, Ekusheva EV, Naprienko MV, Rachin AP, Danilov AB, Kurushina OV, Parfenov VA, Tabeeva GR, Gekht AB, Yahno NN. Diagnosis and treatment of migraine: Recommendations of the Russian experts. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017; 117(1(2)):28-42. (In Russ.) https://doi.org/10.17116/jnevro20171171228-42
  49. Osipova VV, Tabeyeva GR. Pervichnyye golovnyye boli: diagnostika, klinika, terapiya. Prakticheskoye rukovodstvo. M.: OOO «Izdatelstvo «Meditsinskoye informatsionnoye agentstvo»; 2014. (In Russ.)
  50. Kurth T. Migraine with aura and ischemic stroke: which additional factors matter? Stroke. 2007;38(09):2407-2408. https://doi.org/10.1161/strokeaha.107.494179
  51. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated metaanalysis. Am J Med. 2010;123(07):612-624. https://doi.org/10.1016/j.amjmed.2009.12.021
  52. MacClellan LR, Giles W, Cole J, Wozniak M, Stern B, Mitchell BD, Kittner SJ. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke. 2007;38(09):2438-2445. https://doi.org/10.1161/strokeaha.107.488395
  53. Abanoz Y, Gülen Abanoz Y, Gündüz A, Uludüz D, İnce B, Yavuz B, Göksan B. Migraine as a risk factor for young patients with ischemic stroke: a case-control study. Neurol Sci. 2017;38(04):611-617. https://doi.org/10.1007/s10072-017-2810-3
  54. Davis PH. Use of oral contraceptives and postmenopausal hormone replacement: evidence on risk of stroke. Curr Treat Options Neurol. 2008;10(06):468-474. https://doi.org/10.1007/s11940-008-0049-2
  55. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain. 2012;13(03):177-189. https://doi.org/10.1007/s10194-012-0424-y
  56. Sacco S. On behalf of the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC), Merki-Feld G, Ægidius KL, Bitzer J, Canonico M, Kurth T, Lampl C, Lidegaard O, MacGregor E.A, Maassen Van Den Brink A, Mitsikostas DD, Nappi RE, Ntaios G, Sandset PM, Martelletti P. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). The Journal of Headache and Pain. 2017;18:108. https://doi.org/10.1186/s10194-017-0815-1
  57. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;284:72-78. https://doi.org/10.1001/jama.284.1.72
  58. Calhoun A. Combined hormonal contraceptives: is it time to reassess their role in migraine? Headache. 2012;52(04):648-660. https://doi.org/10.1111/j.1526-4610.2011.02051.x
  59. Tepper D. Aura with headache. Headache. 2014;54(06):1115-1116. https://doi.org/10.1111/head.12379
  60. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Nappi G. Migraine with aura and reproductive life events: a case control study. Cephalalgia. 2000;20:701-707. https://doi.org/10.1046/j.1468-2982.2000.00112.x
  61. Sances G, Granella F, Nappi RE, Fignon A, Ghiotto N, Polatti F, Nappi G. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia. 2003;23:197-205. https://doi.org/10.1046/j.1468-2982.2003.00480.x
  62. Maksyukova EV, Osipova VV. Migren u patsiyentov starshey vozrastnoy gruppy: kliniko-psikhologicheskiy analiz. Rossiyskiy Zhurnal Boli. 2011;2:33. (In Russ.)
  63. Chancellor AM, Wroe SJ, Cull RE. Migraine occurring for the first time in pregnancy. Headache. 1990;30:224-227. https://doi.org/10.1111/j.1526-4610.1990.hed3004224.x
  64. Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995;15:140-144. https://doi.org/10.1046/j.1468-2982.1995.015002140.x
  65. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011;84(05):478-485. https://doi.org/10.1016/j.contraception.2011.07.013
  66. Ekusheva EV, Damulin IV. The migrainous attacks during pregnancy: tactic of management of female patients and priorities of therapy. Russian Medical Journal. 2014;3:41-48. (In Russ.)
  67. Ekusheva EV, Damulin IV. Modern approaches to the therapy of migraine during pregnancy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(11):86-94. (In Russ.) https://doi.org/10.17116/jnevro2015115111124-132
  68. Brandlistuen RE, Ystrom E, Nulman I, Koren G, Nordeng H. Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study. Int J Epidemiol. 2013;42(06):1702-1713. https://doi.org/10.1093/ije/dyt183
  69. Bobker S, Klebanoff L, Broner S. Migraine in Women. Neurology. 2017;37(06):601-610. https://doi.org/10.1055/s-0037-1607393
  70. Danielsson B, Wikner BN, Källén B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol. 2014;50:134-137. https://doi.org/10.1016/j.reprotox.2014.10.017
  71. Marchenko A, Etwel F, Olutunfese O, Nickel C, Koren G, Nulman I. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache. 2015;55(04):490-501. https://doi.org/10.1111/head.12500
  72. Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. European Journal of Epidemiology. 2013;28(9):759-769. https://doi.org/10.1007/s10654-013-9831-x
  73. Soldin OP, Dahlin J, O’Mara DM. Triptans in pregnancy. Ther Drug Monit. 2008;30(1):5-9. https://doi.org/10.1097/ftd.0b013e318162c89b
  74. Wainscott G, Sullivan M, Volans G, Wilkinson M. The outcome of pregnancy in women suffering from migraine. Postgrad Med. 1978;54:98-102. https://doi.org/10.1136/pgmj.54.628.98
  75. Banhidy F, Acs N, Horvath-Puho E, Czeizel AE. Pregnancy complications and delivery outcomes in pregnant women with severe. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2007;134(2):157-163. https://doi.org/10.1016/j.ejogrb.2006.08.025
  76. Pakalnis A. Migraine and hormones. Semin Pediatr Neurol. 2016;23(1):92-94. https://doi.org/10.1016/j.spen.2016.01.005
  77. Chen HM, Chen SF, Chen YH, Lin HC. Increased risk of adverse pregnancy outcomes for women with migraines: a nationwide population-based study. Cephalalgia. 2009;30(4):433-438. https://doi.org/10.1111/j.1468-2982.2009.01935.x
  78. Marozio L, Facchinetti F, Allais G, Nappi RE, Enrietti M, Neri I, Picardo E, Benedetto C. Headache and adverse pregnancy outcomes: a prospective study. Eur J Obstet Gynecol Reprod Biol. 2012;161(2):140-143. https://doi.org/10.1016/j.ejogrb.2011.12.030
  79. Facchinetti F, Allais G, Nappi RE, D’Amico R, Marozio L, Bertozzi L, Ornati A, Benedetto C. Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study. Cephalalgia. 2009;29(3):286-292. https://doi.org/10.1111/j.1468-2982.2008.01704.x
  80. Czerwinski S, Gollero J, Qiu C, Sorensen TK, Williams MA. Migraine-asthma comorbidity and risk of hypertensive disorders of pregnancy. Journal of Pregnancy. 2012;1-8. https://doi.org/10.1155/2012/858097
  81. Adeney KL, Williams MA, Miller RS, Frederick IO, Sorensen TK, Luthy DA. Risk of preeclampsia in relation to maternal history of migraine headaches. J Matern Fetal Neonatal Med. 2005;18(3):167-172. https://doi.org/10.1080/14767050500260566
  82. Gelaye B, Larrabure-Torrealva GT, Qiu C, Luque-Fernandez MA, Peterlin BL, Sanchez SE, Williams MA. Fasting lipid and lipoproteins concentrations in pregnant women with a history of migraine. Headache. 2015;55(5):646-657. https://doi.org/10.1111/head.12571
  83. Wabnitz A, Bushnell C. Migraine, cardiovascular disease, and stroke during pregnancy: systematic review of the literature. Cephalalgia. 2015;35(2):132-139. https://doi.org/10.1177/0333102414554113
  84. Qiu C, Frederick IO, Sorensen T, Aurora SK, Gelaye B, Enquobahrie DA, Williams MA. Sleep disturbances among pregnant women with history of migraines: a cross-sectional study. Cephalalgia. 2015;35:1092-1102. https://doi.org/10.1177/0333102415570493
  85. Orta OR, Gelaye B, Qiu C, Stoner L, Williams MA. Depression, anxiety and stress among pregnant migraineurs in pacific northwest cohort. J Affect Disord. 2014;172:390-396. https://doi.org/10.1016/j.jad.2014.10.032
  86. Contag SA, Mertz HL, Bushnell CD. Migraine during pregnancy: is it more than a headache? Nat Rev Neurol. 2009;5(8):449-456. https://doi.org/10.1038/nrneurol.2009.100
  87. Negro A, Delaruelle Z, Ivanova TA, Khan S, Ornello R, Raffaelli B, Terrin A, Reuter U, Mitsikostas DD. Headache and pregnancy: a systematic review. The Journal of Headache and Pain. 2017;18:106. https://doi.org/10.1186/s10194-017-0816-0
  88. Martin VT, Pavlovic J, Fanning KM, Buse DC, Reed ML, Lipton RB. Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American Migraine Prevalence and Prevention Study. Headache. 2016;56(02):292-305. https://doi.org/10.1111/head.12763
  89. Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F, Genazzani AR. Characteristics of headache at menopause: A clinico-epidemiologic study. Maturitas. 1993;17:31-37. https://doi.org/10.1016/0378-5122(93)90121-w
  90. Mattsson P. Hormonal factors in migraine: a population based study of women aged 40 to 74 years. Headache. 2003;43:27-35. https://doi.org/10.1046/j.1526-4610.2003.03005.x
  91. Martin VT, Pavlovic J, Fanning KM, Buse DC, Reed ML, Lipton RB. Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. Headache. 2016;56(2):292-305. https://doi.org/10.1111/head.12763
  92. Makita K, Inagaki M, Kitamura S, Tatsuoka Y. Changes in migraine before and after menopause in Japanese climacteric women. Cephalalgia. 2016;37(11):1088-1092. https://doi.org/10.1177/0333102416653234
  93. Wang SJ, Fuh JL, Lu SR, Juang KD, Wang PH. Migraine prevalence during menopausal transition. Headache. 2004;43:470-478. https://doi.org/10.1046/j.1526-4610.2003.03092.x
  94. Warren MP, Kulak JJr. Is estrogen replacement indicated in perimenopausal women? Clin Obstet Gynecol. 1998;41:976-987. https://doi.org/10.1097/00003081-199812000-00024
  95. MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reproductive Health. 2017;24(1):11-18. https://doi.org/10.1177/2053369117731172
  96. Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol. 2009;32:254-258. https://doi.org/10.1097/wnf.0b013e3181a8c84f
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.